Welcome to Dermbits! Watch short videos of KOLs answering your questionsSee all conditionsAcneActinic KeratosisAestheticsAlopeciaAtopic DermatitisConnective Tissue DiseasesCOVID-19Cutaneous MelanomaEczemaGeneralized Pustular Psoriasis (GPP)Hair and NailsHidradenitis SuppurativaJAK InhibitorsNB-UVBPigmentary DisordersPrecision MedicinePsoriasisPsoriatic ArthritisRosaceaSkin CancerSunscreenTopical TherapiesVitiligoWarts And MolluscumPsoriasisWhat patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast?Featuring Neal Bhatia, MDPsoriasisHow do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone?Featuring Neal Bhatia, MDPsoriasisWhen patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation?Featuring Neal Bhatia, MDPsoriasisIn what situations does apremilast still meaningfully improve a patient’s experience of managing their disease?Featuring Neal Bhatia, MDPsoriasisHow do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”?Featuring Neal Bhatia, MDPsoriasisIn your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy?Featuring Neal Bhatia, MDPsoriasisAre there specific patient populations who are at higher risk for adverse effects from ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat are the considerations for using ixekizumab in patients with a history of serious infections?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisDoes patient weight impact the dosing and efficacy of ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat strategies can be used to taper ixekizumab in patients with sustained remission?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisCan ixekizumab therapy lead to sustained remission or disease modification in patients with psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisShould ixekizumab be used as a monotherapy, or can it be used concomitantly with other therapies?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisAre there any special considerations for transitioning patients with psoriasis from other biologic agents to ixekizumab?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisWhat factors contribute to the progression from mild to severe psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow can early intervention impact the long-term course of psoriasis?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow can dermatologists encourage a holistic approach to psoriasis treatment, including lifestyle modifications and mental health support?Featuring Joel Gelfand, MD, MSCE, FAADPsoriasisHow does ixekizumab impact cardiovascular risk factors in patients with psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisWhat are the long-term outcomes of ixekizumab therapy in terms of durability of response and maintenance of skin clearance?Featuring Tina Bhutani, MD, MASPsoriasisHow does ixekizumab influence the risk of infections in patients with psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisIs there any benefit to extending the dosing interval of ixekizumab in patients with stable psoriasis?Featuring Tina Bhutani, MD, MASPsoriasisIs there any evidence to suggest ixekizumab is more effective in certain psoriasis phenotypes or patient subgroups?Featuring Tina Bhutani, MD, MASPsoriasisWhat lifestyle modifications should be recommended to patients receiving ixekizumab?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the recommended monitoring for patients with psoriasis receiving ixekizumab?Featuring Tina Bhutani, MD, MASPsoriasisWhat is the role of biopsy in confirming a diagnosis of psoriasis?Featuring Tina Bhutani, MD, MASLoad more videos24 of 219Next page
